Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED)

University Hospital, Toulouse24 enrolled

Overview

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.

Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Parkinson Disease

Interventions

Therapeutic education workshopOTHER

Workshop on Parkinson disease drug has several educative sequences (lasting 4hours). * A first round table is organized to know the needs and issues related to drug management of patients. * The 1st educative sequence consists in knowing the different class of dopaminergic drugs and their action. * The 2nd educative sequence leads patients to understand their prescription and be aware of the needs to take pills regularly. * The 3rd educative sequence consists in learning and identifying potentials adverse effects and finds effective strategies to prevent them. At the end, one patient explains its tips and tricks about its drug management

Speaking TherapyOTHER

Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours). This specific time is an exchange between patients with Parkinson disease who feel free to come. It is about sharing its own experience. It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria, * Patients who are already in therapeutic education program ETPARK, * Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug, * Patients with health insurance, * Patients who have signed a written informed consent form. Exclusion Criteria: * Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.), * Patients who has already done workshop on Parkinson disease drug (program ETPARK) * Patients already included in clinical trial during the study, * Patients who have severe psychiatric disorders or dopaminergic psychosis, * Patients with cognitive impairment, * Patients unable to complete the various scales used in the study, * Patients under juridical protection, * Women pregnant or breastfeeding.

Locations (1)

Toulouse University Hospital

Toulouse, Occitanie, France

Outcomes

Primary Outcomes

Evolution of Drug representation in Patients : BMQ

Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".

Time frame: Three months

Evolution of Drug representation in Patients : Verbal association

Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study

Time frame: Three months

Secondary Outcomes

Drug representation in caregivers : Verbal association

Drug representation through verbal association tasks.

Time frame: Day 1

Drug representation in caregivers : BMQ

Drug representation through the Believe about Medicines Questionnaire (BMQ). BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".

Time frame: Day 1

Knowledge about the disease

Evolution between Baseline and three months with a test created for the study. The test have 8 questions with two answers possible : True or False

Time frame: three months

Evolution in life quality : VAS

Evolution in life quality evaluate with Visual Analog Scale (VAS), 0 being the worst quality of life and 10 the best quality of life he can have. Evolution between Baseline and three months

Time frame: three months

Evolution in life quality : PDQ-(39)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.